2025 related articles for article (PubMed ID: 33556464)
21. A Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality.
Fernández-Cruz A; Ruiz-Antorán B; Muñoz-Gómez A; Sancho-López A; Mills-Sánchez P; Centeno-Soto GA; Blanco-Alonso S; Javaloyes-Garachana L; Galán-Gómez A; Valencia-Alijo Á; Gómez-Irusta J; Payares-Herrera C; Morrás-Torre I; Sánchez-Chica E; Delgado-Téllez-de-Cepeda L; Callejas-Díaz A; Ramos-Martínez A; Múñez-Rubio E; Avendaño-Solá C
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32571831
[TBL] [Abstract][Full Text] [Related]
22. High-dose intravenous anakinra treatment is safe and effective in severe and critical COVID-19 patients: a propensity score-matched study in a single center.
Bektaş M; Yüce S; Ay M; Uyar MH; Önder ME; Kılıç Mİ
Inflammopharmacology; 2023 Apr; 31(2):787-797. PubMed ID: 36707494
[TBL] [Abstract][Full Text] [Related]
23. Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study.
Ip A; Berry DA; Hansen E; Goy AH; Pecora AL; Sinclaire BA; Bednarz U; Marafelias M; Berry SM; Berry NS; Mathura S; Sawczuk IS; Biran N; Go RC; Sperber S; Piwoz JA; Balani B; Cicogna C; Sebti R; Zuckerman J; Rose KM; Tank L; Jacobs LG; Korcak J; Timmapuri SL; Underwood JP; Sugalski G; Barsky C; Varga DW; Asif A; Landolfi JC; Goldberg SL
PLoS One; 2020; 15(8):e0237693. PubMed ID: 32790733
[TBL] [Abstract][Full Text] [Related]
24. Comparison of anakinra and tocilizumab in management of severe COVID-19: a retrospective cohort study.
Küçükşahin O; Erden A; Karakaş Ö; Güven SC; Armağan B; Şahiner EŞ; İnan O; Kurtipek AC; Gemcioğlu E; Karaahmetoğlu S; Turan S; İzdeş S; Erdem D; Aypak A; Ayhan M; Akıncı E; Bodur H; Güner R; Omma A; Ateş İ
Turk J Med Sci; 2022 Oct; 52(5):1486-1494. PubMed ID: 36422492
[TBL] [Abstract][Full Text] [Related]
25. Tocilizumab versus anakinra in COVID-19: results from propensity score matching.
Arcani R; Correard F; Suchon P; Kaplanski G; Jean R; Cauchois R; Leprince M; Arcani V; Seguier J; De Sainte Marie B; Andre B; Koubi M; Rossi P; Gayet S; Gobin N; Garrido V; Weiland J; Jouve E; Couderc AL; Villani P; Daumas A
Front Immunol; 2023; 14():1185716. PubMed ID: 37304271
[TBL] [Abstract][Full Text] [Related]
26. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.
Salvarani C; Dolci G; Massari M; Merlo DF; Cavuto S; Savoldi L; Bruzzi P; Boni F; Braglia L; Turrà C; Ballerini PF; Sciascia R; Zammarchi L; Para O; Scotton PG; Inojosa WO; Ravagnani V; Salerno ND; Sainaghi PP; Brignone A; Codeluppi M; Teopompi E; Milesi M; Bertomoro P; Claudio N; Salio M; Falcone M; Cenderello G; Donghi L; Del Bono V; Colombelli PL; Angheben A; Passaro A; Secondo G; Pascale R; Piazza I; Facciolongo N; Costantini M;
JAMA Intern Med; 2021 Jan; 181(1):24-31. PubMed ID: 33080005
[TBL] [Abstract][Full Text] [Related]
27. High-dose methylprednisolone in nonintubated patients with severe COVID-19 pneumonia.
Papamanoli A; Yoo J; Grewal P; Predun W; Hotelling J; Jacob R; Mojahedi A; Skopicki HA; Mansour M; Marcos LA; Kalogeropoulos AP
Eur J Clin Invest; 2021 Feb; 51(2):e13458. PubMed ID: 33219551
[TBL] [Abstract][Full Text] [Related]
28. Prediction of Survival by IL-6 in a Randomized Placebo-Controlled Trial of Anakinra in COVID-19 Cytokine Storm.
Jackson LE; Khullar N; Beukelman T; Chapleau C; Kamath A; Cron RQ; Chatham WW
Viruses; 2023 Sep; 15(10):. PubMed ID: 37896812
[TBL] [Abstract][Full Text] [Related]
29. Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group
Lancet Child Adolesc Health; 2024 Mar; 8(3):190-200. PubMed ID: 38272046
[TBL] [Abstract][Full Text] [Related]
30. Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia.
Pinzón MA; Ortiz S; Holguín H; Betancur JF; Cardona Arango D; Laniado H; Arias Arias C; Muñoz B; Quiceno J; Jaramillo D; Ramirez Z
PLoS One; 2021; 16(5):e0252057. PubMed ID: 34033648
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study.
de la Calle C; López-Medrano F; Pablos JL; Lora-Tamayo J; Maestro-de la Calle G; Sánchez-Fernández M; Fernández-Ruiz M; Pérez-Jacoiste Asín MA; Caro-Teller JM; García-García R; Catalán M; Martínez-López J; Sevillano Á; Origüen J; Ripoll M; San Juan R; Lalueza A; de Miguel B; Carretero O; Aguilar F; Gómez C; Paz-Artal E; Bueno H; Lumbreras C; Aguado JM
Int J Infect Dis; 2021 Apr; 105():319-325. PubMed ID: 33592340
[TBL] [Abstract][Full Text] [Related]
32. Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation.
Della-Torre E; Lanzillotta M; Campochiaro C; Cavalli G; De Luca G; Tomelleri A; Boffini N; De Lorenzo R; Ruggeri A; Rovere-Querini P; Castagna A; Landoni G; Tresoldi M; Ciceri F; Zangrillo A; Dagna L
Front Immunol; 2021; 12():675678. PubMed ID: 33995419
[TBL] [Abstract][Full Text] [Related]
33. IL-1 Receptor Antagonist Anakinra in the Treatment of COVID-19 Acute Respiratory Distress Syndrome: A Retrospective, Observational Study.
Franzetti M; Forastieri A; Borsa N; Pandolfo A; Molteni C; Borghesi L; Pontiggia S; Evasi G; Guiotto L; Erba M; Pozzetti U; Ronchetti A; Valsecchi L; Castaldo G; Longoni E; Colombo D; Soncini M; Crespi S; Maggiolini S; Guzzon D; Piconi S
J Immunol; 2021 Apr; 206(7):1569-1575. PubMed ID: 33547169
[TBL] [Abstract][Full Text] [Related]
34. Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID-19: A Case Series.
Navarro-Millán I; Sattui SE; Lakhanpal A; Zisa D; Siegel CH; Crow MK
Arthritis Rheumatol; 2020 Dec; 72(12):1990-1997. PubMed ID: 32602262
[TBL] [Abstract][Full Text] [Related]
35. Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19).
Urwyler P; Charitos P; Moser S; Heijnen IAFM; Trendelenburg M; Thoma R; Sumer J; Camacho-Ortiz A; Bacci MR; Huber LC; Stüssi-Helbling M; Albrich WC; Sendi P; Osthoff M
Trials; 2021 Jan; 22(1):1. PubMed ID: 33397449
[TBL] [Abstract][Full Text] [Related]
36. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.
Hermine O; Mariette X; Tharaux PL; Resche-Rigon M; Porcher R; Ravaud P;
JAMA Intern Med; 2021 Jan; 181(1):32-40. PubMed ID: 33080017
[TBL] [Abstract][Full Text] [Related]
37. Characteristics and clinical outcome in 312 patients with moderate to severe pneumonia due to SARS-COV-2 and hyperinflammation treated with anakinra and corticosteroids: A retrospective cohort study.
Aomar-Millán IF; de Victoria-Carazo JM; Fernández Reyes D; Torres-Parejo Ú; Pérez Fernández L; Martínez-Diz S; Ceballos Torres A; López Gómez J; Bizzarri F; Raya Álvarez E; Salvatierra J
PLoS One; 2023; 18(3):e0283529. PubMed ID: 36961847
[TBL] [Abstract][Full Text] [Related]
38. Association of Serum Ferritin Levels and Methylprednisolone Treatment With Outcomes in Nonintubated Patients With Severe COVID-19 Pneumonia.
Papamanoli A; Kalogeropoulos AP; Hotelling J; Yoo J; Grewal P; Predun W; Jacob RP; Cao K; Marcos LA; Skopicki HA
JAMA Netw Open; 2021 Oct; 4(10):e2127172. PubMed ID: 34605919
[TBL] [Abstract][Full Text] [Related]
39. Intravenous methylprednisolone with or without tocilizumab in patients with severe COVID-19 pneumonia requiring oxygen support: A prospective comparison.
Hamed DM; Belhoul KM; Al Maazmi NA; Ghayoor F; Moin M; Al Suwaidi M; Narainen M; Makki M; AbdulRahman M
J Infect Public Health; 2021 Aug; 14(8):985-989. PubMed ID: 34153729
[TBL] [Abstract][Full Text] [Related]
40. Multi-centre, three arm, randomized controlled trial on the use of methylprednisolone and unfractionated heparin in critically ill ventilated patients with pneumonia from SARS-CoV-2 infection: A structured summary of a study protocol for a randomised controlled trial.
Busani S; Tosi M; Mighali P; Vandelli P; D'Amico R; Marietta M; Forfori F; Donati A; Cinnella G; De Monte A; Pasero D; Bellani G; Tascini C; Foti G; Ranieri M; Girardis M
Trials; 2020 Aug; 21(1):724. PubMed ID: 32807241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
